IN VIVO mRNA transfection reagent
The Viromer® IN VIVO mRNA transfection reagent is a lyophilized powder containing Viromer® nanoparticles. It only needs to be rehydrated with the diluted target mRNA to form active particles.
The Systemic Kit contains:
Lipocalyx Viromer® IN VIVO mRNA transfection reagent facilitates effective systemic delivery and protein expression in animals. Viromer® IN VIVO reagents are loaded with an mRNA provided by the user by simply adding an mRNA solution to the lyophilized product. Systemic injection into the tail vein of a mouse or another animal results in rapid protein expression in liver and spleen. For luciferase, substantial activity as early as two hours upon injection was detected and the signal could be tracked for up to 44 hours.
A systemic (intravenous) injection of 10µg mRNA or less per mouse results in a specific targeting of the spleen. Delivery of mRNA results in the local production of the encoded protein and an expression of 150ng luciferase per gram of spleen tissue 6h post-injection was reported. Proteins having an export sequence or signal peptide such as EPO are excreted into the circulation; serum levels of 60 ng/mL upon a single injection of 10µg mRNA as early as 2h after the injection have been measured.
Intravenous injections of 20 to 40µg mRNA per mouse targets the liver in addition to spleen. Typical levels of expression are 50 and 400ng luciferase per gram of liver or spleen tissue, respectively. For EPO, a secreted protein, the injection of 30µg mRNA complexed to Viromer gave serum concentrations of 160 ng/mL at 2h after the injection.
Given the specific targeting to spleen and the very high performance of Viromer with macrophages, the technology is ideally for immune-related applications such as:
Apart from targeted approaches to the immune system, the Viromer IN VIVO for the first time facilitates the effective expression of a variety of proteins from mRNA.
The reconstituted Viromer IN VIVO has the following specifications: